Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Titel:
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Auteur:
Daver, Naval G Montesinos, Pau DeAngelo, Daniel J Wang, Eunice S Papadantonakis, Nikolaos Todisco, Elisabetta Sweet, Kendra L Pemmaraju, Naveen Lane, Andrew A Torres-Miñana, Laura Thompson, James E Konopleva, Marina Y Sloss, Callum M Watkins, Krystal Bedse, Gaurav Du, Yining Malcolm, Kara E Zweidler-McKay, Patrick A Kantarjian, Hagop M